The Senate Committee on Health, Education, Labor, and Pensions was still scheduled as of Tuesday afternoon to vote on whether to advance Overton’s nomination to lead the Food and Drug Administration. The panel is chaired by Sen. Bill Cassidy, a Louisiana Republican who is set to leave the Senate after losing his May primary to a Trump-backed challenger.
The alliance, which opposed Overton’s nomination in September, says she has a record of seeking to restrict abortion access, including medication abortion. Critics have also raised concerns about her views on vaccines, scientific research and the FDA’s independence.
Kayla Hancock, director of Protect Our Care’s Public Health Project, urged Cassidy to block the nomination. She criticized his vote to confirm Health and Human Services Secretary Robert F. Kennedy Jr. and warned that Overton could undermine public health and access to medication abortion. Hancock also accused Overton of supporting FDA actions involving fruit-flavored vapes marketed to children. Those claims and assessments were made by opponents of the nomination.
Robert Steinbrook, director of Public Citizen’s Health Research Group, cited Overton’s lack of managerial experience and her call for scientific journals to prioritize “conservative-based” science. He also said she opposes expanded access to medication abortion and supports separating the combined measles, mumps and rubella vaccine into individual shots.




Comments (0)
No comments yet. Be the first!